GLP-1 drug manufacturers face nearly 100 lawsuits alleging the medications caused vision loss through a rare eye condition called NAION. While some research suggests a potential link, other studies found no association, and health authorities say evidence remains insufficient to establish causation. Novo Nordisk and Eli Lilly deny any significant relationship between their drugs and the condition.
Hundreds of lawsuits have been filed against GLP-1 drug makers Eli Lilly and Novo Nordisk alleging their weight-loss medications, including Ozempic and Mounjaro, caused permanent vision loss through a condition called NAION. The plaintiffs claim the drugmakers failed to warn patients of this side effect, though it appears on labels in some other countries. Both companies deny a significant link between their drugs and vision loss.
Hundreds of lawsuits have been filed against GLP-1 drug makers Eli Lilly and Novo Nordisk, with patients alleging that popular weight-loss medications like Ozempic, Wegovy, and Mounjaro caused permanent vision loss through a condition called NAION. The plaintiffs claim the drugmakers failed to warn patients of this serious side effect, which appears on labels in some countries but not the United States. Both companies deny any significant link between their medications and vision loss.
Hundreds of consumers are suing manufacturers of GLP-1 weight-loss drugs, claiming they cause NAION, a rare eye condition leading to sudden vision loss. Research shows mixed results with some studies finding increased NAION risk in semaglutide users, though observational evidence cannot prove causation, and regulatory agencies remain under investigation without issuing formal warnings.
Hundreds of Americans are suing GLP-1 drug makers after experiencing vision loss, including a Georgia nurse who lost sight in one eye while taking Wegovy. Patients report they were not adequately warned about the rare eye condition NAION, though drug companies dispute the link and claim labels contain appropriate warnings.